Evidence map›Paper›PMID 34094178›Full record

ArticleChemical science2020

Production of novel pladienolide analogues through native expression of a pathway-specific activator.

Thomas J Booth, John A Kalaitzis, Daniel Vuong, Andrew Crombie, Ernest Lacey, Andrew M Piggott, Barrie Wilkinson

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Recently Discovered Secondary Metabolites fromMolecules (Basel, Switzerland) · 2022
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Thomas J BoothDepartment of Molecular Microbiology, John Innes Centre Norwich Research Park Norwich NR4 7UH UK barrie.wilkinson@jic.ac.uk.ORCID https://orcid.org/0000-0002-6134-1488
John A KalaitzisDepartment of Molecular Sciences, Macquarie University NSW 2109 Australia andrew.piggott@mq.edu.au.
Daniel VuongMicrobial Screening Technologies Smithfield NSW 2164 Australia elacey@microbialscreening.com.
Andrew CrombieMicrobial Screening Technologies Smithfield NSW 2164 Australia elacey@microbialscreening.com.
Ernest LaceyMicrobial Screening Technologies Smithfield NSW 2164 Australia elacey@microbialscreening.com.ORCID https://orcid.org/0000-0002-5387-2721
Andrew M PiggottDepartment of Molecular Sciences, Macquarie University NSW 2109 Australia andrew.piggott@mq.edu.au.ORCID https://orcid.org/0000-0002-5308-5314
Barrie WilkinsonDepartment of Molecular Microbiology, John Innes Centre Norwich Research Park Norwich NR4 7UH UK barrie.wilkinson@jic.ac.uk.ORCID https://orcid.org/0000-0001-7646-7174
John Innes Centre · GBMacquarie University · AU

Funding

Biotechnology and Biological Sciences Research Council BBS/E/J/000PR9790
6 · The paper itself

Abstract

Aberrant splicing of pre-mRNA is implicated in many human genetic disorders. Small molecules that target the spliceosome are important leads as therapeutics and research tools, and one compound of significant interest is the polyketide natural product pladienolide B. Here, we describe the reactivation of quiescent pladienolide B production in the domesticated lab strain

Identifiers

PMID34094178
PMCPMC8163091
OpenAlexW3043002249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.